Amplia Therapeutics CEO outlines 2023 milestones
News release
by
Amplia Therapeutics Ltd
Melbourne, Victoria
|
January 30, 2023 04:00 PM Eastern Standard Time
Amplia Therapeutics Ltd (ASX:ATX) CEO Dr Chris Burns speaks with Proactive following his move into the leadership role late last year. Amplia is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in cancer and Amplia has a particular development focus in fibrotic tumours such as pancreatic and ovarian cancers.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
